Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 1.000 | definitive | 0.986 | 50 | 146 | 1996 | 2020 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.700 | strong | 0.978 | 35 | 60 | 1991 | 2020 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.600 | strong | 1.000 | 0 | 0 | 2017 | 2017 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.420 | strong | 1.000 | 0 | 0 | 1996 | 2019 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
group | 0.400 | strong | 1.000 | 0 | 0 | 2017 | 2017 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.400 | strong | 1.000 | 0 | 0 | 1996 | 2006 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.110 | None | 1.000 | 1 | 1 | 2015 | 2018 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.110 | None | 1.000 | 0 | 0 | 2017 | 2017 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 1.000 | 3 | 1 | 2018 | 2018 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 1.000 | 2 | 2 | 2010 | 2018 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.100 | None | 1.000 | 1 | 1 | 2010 | 2010 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 1.000 | 1 | 4 | 2018 | 2018 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2010 | 2010 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.100 | None | 1.000 | 1 | 1 | 2012 | 2012 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2013 | 2013 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.100 | None | 0 | 0 | |||||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.100 | None | 0 | 0 | |||||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.100 | None | 0 | 0 |